DOP2002000385A - Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 - Google Patents

Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3

Info

Publication number
DOP2002000385A
DOP2002000385A DO2002000385A DO2002000385A DOP2002000385A DO P2002000385 A DOP2002000385 A DO P2002000385A DO 2002000385 A DO2002000385 A DO 2002000385A DO 2002000385 A DO2002000385 A DO 2002000385A DO P2002000385 A DOP2002000385 A DO P2002000385A
Authority
DO
Dominican Republic
Prior art keywords
beta
adrenorecepting
agonists
chroman derivatives
useful substitutes
Prior art date
Application number
DO2002000385A
Other languages
English (en)
Inventor
Ming Wang
Derek B Lowe
William H Bullock
Wendy Lee
Stephen J O Connor
Gaetan H Ladouceur
Ann-Marie Campbell
Miao Dai
Robert Dally
Jacques Dumas
Holia N Hatoum Mokdad
Uday Khire
Qingjie Liu
Steven R Magnuson
Ning Ql
Tatiana E Shelekhin
Quanrong Shen
Roger A Smith
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of DOP2002000385A publication Critical patent/DOP2002000385A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a nuevos derivados de cromano 2,6-sustituidos que son útiles en el tratamiento de condiciones intermediadas por el adrenoreceptor beta-3
DO2002000385A 2001-04-23 2002-04-22 Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 DOP2002000385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28571901P 2001-04-23 2001-04-23
US32451801P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
DOP2002000385A true DOP2002000385A (es) 2004-01-31

Family

ID=26963345

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000385A DOP2002000385A (es) 2001-04-23 2002-04-22 Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3

Country Status (9)

Country Link
US (3) US6660752B2 (es)
EP (1) EP1389202B1 (es)
JP (1) JP2004532227A (es)
AR (1) AR035858A1 (es)
DE (1) DE60201437T2 (es)
DO (1) DOP2002000385A (es)
ES (1) ES2230487T3 (es)
PE (1) PE20021073A1 (es)
WO (1) WO2002085891A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
NZ550441A (en) * 2004-05-05 2009-07-31 Hoffmann La Roche Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
ATE455755T1 (de) * 2004-12-21 2010-02-15 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen
BRPI0515830A (pt) 2004-12-21 2008-08-05 F Hoffmann La Roche derivados de cromano e usos dos mesmos no tratamento de distúrbios do sistema nervoso central
WO2006066748A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof as 5-ht antagonists
PL1831191T3 (pl) * 2004-12-21 2008-10-31 Hoffmann La Roche Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
WO2006066745A1 (en) * 2004-12-21 2006-06-29 F.Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof
MX2007009783A (es) 2005-02-17 2007-08-22 Wyeth Corp Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilfusionados.
WO2007051735A1 (en) * 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
UA97474C2 (ru) 2006-03-31 2012-02-27 Новартис Аг Соединения для лечения нарушений, связанных с активностью dgat1
CN101472884A (zh) * 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 1,2,3,4-四氢化萘和茚满衍生物及其用途
JP2009541249A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
BRPI0713502A2 (pt) * 2006-06-20 2012-03-13 F. Hoffmann-La Roche Ag derivados de tetralina de arilsulfonamidil e empregos destes
CA2844128C (en) * 2011-08-30 2020-09-01 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
UA118444C2 (uk) * 2013-01-09 2019-01-25 Басф Агро Б.В. Спосіб одержання заміщених оксиранів і триазолів
AU2014300629A1 (en) * 2013-06-24 2015-12-24 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
US10512267B2 (en) 2013-07-08 2019-12-24 BASF Agro, B.V. Compositions comprising a triazole compound and a biopesticide
EA037646B1 (ru) * 2013-12-12 2021-04-27 Басф Агро Б.В. Способ получения замещенных триазолов
CN106793776A (zh) 2014-06-25 2017-05-31 巴斯夫农业公司 农药组合物
MX2017000317A (es) 2014-07-08 2017-08-25 Basf Agro Bv Proceso para la preparacion de oxiranos y triazoles.
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
CN107848922A (zh) 2015-05-08 2018-03-27 巴斯夫农业公司 柠檬烯‑4‑醇的制备方法
BR112017023932A2 (pt) 2015-05-08 2018-07-17 Basf Agro Bv processo para a preparação de epóxido de terpinoleno
WO2017095722A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
WO2017095723A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
EP3429358A1 (en) 2016-03-16 2019-01-23 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on fruits
RU2754614C2 (ru) 2016-03-16 2021-09-03 Басф Се Применение тетразолинонов для борьбы с устойчивыми фитопатогенными грибами на злаковых культурах
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
US10640477B2 (en) 2016-06-15 2020-05-05 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
WO2017215928A1 (en) 2016-06-15 2017-12-21 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
GB201803394D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706764A (en) 1969-04-16 1972-12-19 Yoshitomi Pharmaceutical Phenethylaminomethyl-chromanones and- thiochromanones
US3803176A (en) 1969-05-09 1974-04-09 Novo Terapeutisk Labor As Sulfonylurea derivatives
GB1499323A (en) 1974-03-22 1978-02-01 Fisons Ltd 6-substituted chromones and chromanones
DE3275295D1 (en) 1981-11-12 1987-03-05 Fisons Plc Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them
EP0091749A3 (en) 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3411992A1 (de) 1984-03-31 1985-10-10 Bayer Ag, 5090 Leverkusen Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4727877A (en) * 1984-12-18 1988-03-01 Medtronic, Inc. Method and apparatus for low energy endocardial defibrillation
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5117824A (en) * 1990-11-14 1992-06-02 Medtronic, Inc. Apparatus for monitoring electrical physiologic signals
US5163427A (en) * 1990-11-14 1992-11-17 Medtronic, Inc. Apparatus for delivering single and multiple cardioversion and defibrillation pulses
US5129392A (en) * 1990-12-20 1992-07-14 Medtronic, Inc. Apparatus for automatically inducing fibrillation
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
CN1129443A (zh) 1993-06-14 1996-08-21 美国辉瑞有限公司 仲胺用作治糖尿病和治肥胖病药物
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5541197A (en) 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
JPH08198866A (ja) 1995-01-20 1996-08-06 Tokyo Tanabe Co Ltd 新規２−アミノ−１−フェニルエタノール化合物
US5674254A (en) * 1995-05-22 1997-10-07 Vitatron Medical, B.V. Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
FR2746395B1 (fr) 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
EA199900692A1 (ru) 1997-01-28 2000-02-28 Мерк Энд Ко., Инк. БЕНЗОЛСУЛЬФАМИДЫ ТИАЗОЛА КАК βАГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА И ОЖИРЕНИЯ
US5741312A (en) * 1997-03-12 1998-04-21 Vitatron Medical, B.V. Pacemaker system and method with improved capture detection and threshold search
US6469031B1 (en) * 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6051586A (en) 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
ID26524A (id) * 1997-12-19 2001-01-11 Bayer Ag Turunan-turunan kroman tersubstitusi karboksil bermanfaat sebagai agonis beta-3 adrenoreseptor
US6052621A (en) * 1998-01-27 2000-04-18 Vitatron Medical B.V. System and method for inducing tachycardia
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
EP1178855B1 (en) * 1999-05-12 2006-08-02 Medtronic, Inc. Monitoring apparatus using wavelet transforms for the analysis of heart rhythms
US6647292B1 (en) * 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6675042B2 (en) * 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology

Also Published As

Publication number Publication date
PE20021073A1 (es) 2002-12-12
DE60201437T2 (de) 2005-12-15
WO2002085891A1 (en) 2002-10-31
ES2230487T3 (es) 2005-05-01
AR035858A1 (es) 2004-07-21
EP1389202A1 (en) 2004-02-18
DE60201437D1 (de) 2004-11-04
US20030078260A1 (en) 2003-04-24
US20040072828A1 (en) 2004-04-15
EP1389202B1 (en) 2004-09-29
JP2004532227A (ja) 2004-10-21
US6919371B2 (en) 2005-07-19
US6660752B2 (en) 2003-12-09
US20050215594A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
DOP2002000385A (es) Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3
BR0116026A (pt) Imidazoquinolinas substituìdas por tioéter
HN2003000416A (es) Derivados de pirrolopirimidina
CR8410A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
BR0308639A (pt) Composições, artigo, método para repelir qualquer um ou mais membros do grupo de insetos, processo para a produção de di-hidronepetalactona
UY27065A1 (es) Agonistas de beta-3 adreno-receptores de derivados de aminometil cromano di-sustituido
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
BR0211905A (pt) Dialdeìdos de rapamicina
CR9149A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10
BR0113184A (pt) Implante artificial e processo para produzir o mesmo
ATE468910T1 (de) Mischflügel mit lösbarem verschleisselement
BRPI0413180A (pt) gorduras de baixo teor de ácido trans-groxo e composições de gorduras, e métodos de fazer as mesmas
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
AR032499A1 (es) Composiciones
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
GT200600326A (es) Diazepinoquinolinas, sintesis de las mismas e intermediarios de las mismas
ECSP045277A (es) Composición oftálmica que comprende ascomicina
BR0212246A (pt) Composição indutora da resistência a doença de planta, método para controlar uma doença de planta, e, processo para a produção de uma composição
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
PT1626974E (pt) Benzopiranos substituídos como agonistas selectivos do receptor beta de estrogénio
BR9814302A (pt) Derivados de cromano de carboxila substituìda úteis como agonistas do adrenorreceptor beta 3
PA8437901A1 (es) Procedimientos e intermedios para preparar derivados de cromanol sustituidos
UY27268A1 (es) Derivados de cromano 2, 6-sustituidos útiles como agonistas adrenorrecptores beta-3
TW200738689A (en) Salts and polymorphs of a VEGF-R inhibitor